LEIDEN, The Netherlands, May 6, 2010 Dutchbiopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; SwissExchange: CRX) today announced the award from UNICEF of an additional $110million to supply its paediatric vaccine Quinvaxem(R) to the developingworld. Paediatric vaccination plays an important role in contributing toachieving the Millennium Development Goals set by the United Nations, inparticular the target of reducing under-five mortality rate by two-thirdsbetween 1990 and 2015. "We are proud to be able to deliver significant amountof additional vaccine orders at short notice," said Ronald Brus, Crucell'sChief Executive Officer. "The capacity and reliability of Crucell'smanufacturing and logistical systems allows us to deliver high quality andsafe vaccines to protect young children from life threatening diseases in theworld's developing countries. As a responsible and reliable partner, we thuscontribute to the success of the Global Alliance for Vaccines andImmunisation (GAVI Alliance) in accelerating access to these vaccines acrossthe globe."
From 2006-2009 as part of the Extended Program for Immunization, over 130million doses of Quinvaxem(R) have been delivered to more than 50 countries.Crucell has been increasing its production capacity over the last few yearsin order to meet the growing demand for paediatric vaccines from thedeveloping world.
Quinvaxem(R) is the only fully liquid pentavalent DTwP-HepB-Hib vaccinethat is free from the preservative thiomersal. It is an optimal solution forprotection against five potentially deadly childhood diseases: diphtheria,tetanus, pertussis, Haemoplilus influenza type b infection and hepatitis B.Quinvaxem(R) is ready for use without further preparation steps by healthcareworkers in the field, which offers major healthcare advantages for thesecountries with a challenging infrastructure and hygiene problems.
This latest order brings the overall value of tenders awarded to Crucellfor the period of 2010-2012 to $410 million. This is in addition to the $500million obtained over the tender period 2007-2009. They bring the total valueof contracts awarded since the launch of Quinvaxem(R) at the end of 2006 to$910 million. During the first tender round in 2006, Crucell was initiallyawarded $230 million (December 2006) and received additional incrementalawards of $130 million and $140 million in May and September 2008,respectively.
This press release contains forward-looking statements that involveinherent risks and uncertainties. We have identified certain importantfactors that may cause actual results to differ materially from thosecontained in such forward-looking statements. For information relating tothese factors please refer to our Form 20-F, as filed with the US Securitiesand Exchange Commission on April 7, 2010, in the section entitled 'RiskFactors'. The Company prepares its financial statements under InternationalFinancial Reporting Standards (IFRS).
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is aglobal biopharmaceutical company focused on research development, productionand marketing of vaccines, proteins and antibodies that prevent and/or treatinfectious diseases. In 2009 alone, Crucell distributed more than 115 millionvaccine doses in more than 100 countries around the world, with the fastmajority of doses (97%) going to developing countries. Crucell is one of themajor suppliers of vaccines to UNICEF and the developing world. Crucell wasthe first manufacturer to launch a fully-liquid pentavalent vaccine calledQuinvaxem(R). Quinvaxem(R) protects against five important childhood diseasesand over 130 million doses have been sold since its launch in 2006 in morethan 50 GAVI countries. Through Quinvaxem(R) and its innovation, Crucell hasbecome a major partner in protecting children in developing countries.Crucell's core portfolio also includes a vaccine against hepatitis B and avirosome-adjuvanted vaccine against influenza. Crucell also markets travelvaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine andthe only aluminum-free hepatitis A vaccine on the market. The Company has abroad development pipeline, with several product candidates based on itsunique PER.C6(R) production technology. The Company licenses its PER.C6(R)technology and other technologies to the biopharmaceutical industry.Important partners and licensees include Johnson & Johnson, DSM Biologics,sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell isheadquartered in Leiden, the Netherlands, with subsidiaries in Argentina,China, Italy, Korea, Spain, Sweden, Switzerland, UK and the USA. The Companyemploys over 1200 people. For more information, please visithttp://www.crucell.com.
SOURCE Crucell N.V